Editing Instem plc: $12m five-year agreement with Leading Contract Research Organisation
The edit can be undone. Please check the comparison below to verify that this is what you want to do, and then publish the changes below to finish undoing the edit.
Latest revision | Your text | ||
Line 1: | Line 1: | ||
== Summary == | == Summary == | ||
On 2nd September 2022, Instem plc (AIM: INS), a leading provider of IT solutions to the global life sciences market, announced a five-year agreement, worth over $12 million, with a leading global contract research organisation ("CRO" or "Client") to support over 2,000 users worldwide in their clinical trial analysis. | On 2nd September 2022, Instem plc (AIM: INS), a leading provider of IT solutions to the global life sciences market, announced a five-year agreement, worth over $12 million, with a leading global contract research organisation ("CRO" or "Client") to support over 2,000 users worldwide in their clinical trial analysis. |